Levalbuterol sulfate is under clinical development by Cipher Pharmaceuticals and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). According to GlobalData, Phase II drugs for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Levalbuterol sulfate LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Levalbuterol sulfate overview

Levalbuterol sulfate (ASF-1096) is under development for the treatment of discoid lupus erythematosus and anal fissures. It is applied as a topical cream. ASF-1096 is a sulphate salt of R-salbutamol, also called levosalbutamol or levalbutarol. Salbutamol is a selective beta 2-adrenergic receptor agonist. The drug candidate is developed using beta2 adrenoceptor technology. It was also under development for subacute cutaneous lupus erythematosus.

Cipher Pharmaceuticals overview

Cipher Pharmaceuticals (Cipher) is a pharmaceutical company that develops skin care solutions. The company’s major products include actikerall, to treat slightly palpable and moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp; epuris, to treat severe nodular and inflammatory acne, acne con globate and recalcitrant acne; ozanex for the topical treatment of impetigo, vaniqa, to treat unwanted facial hair in women. its pipeline products include treprostinil sodium, to treat pulmonary arterial hypertension; MOB-015, to treat onychomycosis; CF-101, to treat severe plaque psoriasis and rheumatoid arthritis, DTR-001, for tattoo removal. The company carries out various phases of clinical trials. Cipher is headquartered in Mississauga, Ontario, Canada.

For a complete picture of Levalbuterol sulfate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.